American Journal of Clinical Dermatology

, Volume 14, Issue 4, pp 261–272 | Cite as

Immunotherapy for the Management of Advanced Melanoma: The Next Steps

  • Dragoslav Zikich
  • Jacob Schachter
  • Michal J. Besser
Review Article


Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma.


Melanoma Metastatic Melanoma Melanoma Patient Objective Response Rate Ipilimumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to prepare this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol. 2007;34(6):532–45.PubMedGoogle Scholar
  2. 2.
    Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365(9460):687–701.PubMedGoogle Scholar
  3. 3.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.PubMedGoogle Scholar
  4. 4.
    Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405–13.PubMedGoogle Scholar
  5. 5.
    Hafler DA. Cytokines and interventional immunology. Nat Rev Immunol. 2007;7(6):423.Google Scholar
  6. 6.
    Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17(2):117–27. doi: 10.1097/CMR.0b013e328042bb36.PubMedGoogle Scholar
  7. 7.
    Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Nat Cancer Inst. 2010;102(7):493–501.PubMedGoogle Scholar
  8. 8.
    Eggermont AMM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;24:2012.Google Scholar
  9. 9.
    Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (Oxford, England: 1990). 2012;48(2):218–25.Google Scholar
  10. 10.
    Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 2007;8(12):1142–8.PubMedGoogle Scholar
  11. 11.
    Bamford RN, Grant AJ, Burton JD, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Nat Acad Sci. 1994;91(11):4940–4.PubMedGoogle Scholar
  12. 12.
    Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6(11):1142–51.PubMedGoogle Scholar
  13. 13.
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105.PubMedGoogle Scholar
  14. 14.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17(3):968.PubMedGoogle Scholar
  15. 15.
    Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889–97.PubMedGoogle Scholar
  16. 16.
    Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907–13.PubMedGoogle Scholar
  17. 17.
    Legha SS, Gianan MA, Plager C, et al. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996;77(1):89–96.PubMedGoogle Scholar
  18. 18.
    Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-[bgr] are required for differentiation of human TH17 cells. Nature. 2008;454(7202):350–2.PubMedGoogle Scholar
  19. 19.
    Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57–63.PubMedGoogle Scholar
  20. 20.
    Li Y, Yee C. IL-21-mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood. 2008;111(1):229–35.PubMedGoogle Scholar
  21. 21.
    Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature. 2007;448(7152):484–7.PubMedGoogle Scholar
  22. 22.
    Petrella TM, Tozer R, Belanger K, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol. 2012;30(27):3396–401.PubMedGoogle Scholar
  23. 23.
    Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.PubMedGoogle Scholar
  24. 24.
    Williams P, Galipeau J. GMCSF-Interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. J Intern Med. 2011;269(1):74–84.PubMedGoogle Scholar
  25. 25.
    Caserta S, Alessi P, Basso V, et al. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4+ T cells. Eur J Immunol. 2010;40(2):470–9.PubMedGoogle Scholar
  26. 26.
    Dubsky P, Saito H, Leogier M, et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol. 2007;37(6):1678–90.PubMedGoogle Scholar
  27. 27.
    Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13(16):4677–85.PubMedGoogle Scholar
  28. 28.
    Enk AH, Nashan D, Rübben A, et al. High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer. 2000;88(9):2042–6.PubMedGoogle Scholar
  29. 29.
    Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003;89(9):1620–6.PubMedGoogle Scholar
  30. 30.
    Sondel P, Hank J, Albertini M, et al. Novel strategies for cytokine administration via targetting. In: Caligiuri M, Lotze M, editors. Cytokines in the genesis and treatment of cancer. New York: Humana Press; 2007. p. 399–422.Google Scholar
  31. 31.
    Eigentler TK, Weide B, de Braud F, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res. 2011;17(24):7732–42.PubMedGoogle Scholar
  32. 32.
    Park J, Wrzesinski SH, Stern E, et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater. 2012;11(10):895–905.PubMedGoogle Scholar
  33. 33.
    Kaufman HL. Vaccines for melanoma and renal cell carcinoma. Semin Oncol. 2012;39(3):263–75.PubMedGoogle Scholar
  34. 34.
    Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15.PubMedGoogle Scholar
  35. 35.
    Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27.PubMedGoogle Scholar
  36. 36.
    Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11(22):8055–62.PubMedGoogle Scholar
  37. 37.
    Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther. 2002;2(3):335–42.PubMedGoogle Scholar
  38. 38.
    Berd D, Sato T, Cohn H, et al. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer. 2001;94(4):531–9.PubMedGoogle Scholar
  39. 39.
    Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010;20(3):218–26.PubMedGoogle Scholar
  40. 40.
    Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.PubMedGoogle Scholar
  41. 41.
    Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–71.PubMedGoogle Scholar
  42. 42.
    Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol. 1999;11(2):203–10.PubMedGoogle Scholar
  43. 43.
    Peach RJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med. 1994;180(6):2049–58.PubMedGoogle Scholar
  44. 44.
    Alegre M-L, Shiels H, Thompson CB, et al. Expression and function of CTLA-4 in Th1 and Th2 Cells. J Immunol. 1998;161(7):3347–56.PubMedGoogle Scholar
  45. 45.
    Munn DH, Sharma MD, Mellor AL. Ligation of B7–1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004;172(7):4100–10.PubMedGoogle Scholar
  46. 46.
    Norde WJ, Hobo W, van der Voort R, et al. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood. 2012;120(4):728–36.PubMedGoogle Scholar
  47. 47.
    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.PubMedGoogle Scholar
  48. 48.
    Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol. 2008;26(suppl):485. abstr LBA9011.Google Scholar
  49. 49.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedGoogle Scholar
  50. 50.
    Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.PubMedGoogle Scholar
  51. 51.
    Freeman GJ. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Nat Acad Sci. 2008;105(30):10275–6.PubMedGoogle Scholar
  52. 52.
    Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.PubMedGoogle Scholar
  53. 53.
    Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175–86.PubMedGoogle Scholar
  54. 54.
    Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.PubMedGoogle Scholar
  55. 55.
    Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.PubMedGoogle Scholar
  56. 56.
    Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Nat Acad Sci. 2010;107(9):4275–80.PubMedGoogle Scholar
  57. 57.
    Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18(5):565–71.PubMedGoogle Scholar
  58. 58.
    Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6(6):433–46.PubMedGoogle Scholar
  59. 59.
    Ebrahimnejad A, Streichert T, Nollau P, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol. 2004;165(5):1781–7.PubMedGoogle Scholar
  60. 60.
    Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20(10):2530–6.PubMedGoogle Scholar
  61. 61.
    Brümmer J, Ebrahimnejad A, Flayeh R, et al. cis Interaction of the cell adhesion molecule CEACAM1 with integrin β3. Am J Pathol. 2001;159(2):537–46.PubMedGoogle Scholar
  62. 62.
    Markel G, Seidman R, Cohen Y, et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology. 2009;126(2):186–200.PubMedGoogle Scholar
  63. 63.
    Markel G, Wolf D, Hanna J, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Investig. 2002;110(7):943–53.PubMedGoogle Scholar
  64. 64.
    Azuz-Lieberman N, Markel G, Mizrahi S, et al. The involvement of NK cells in ankylosing spondylitis. Int Immunol. 2005;17(7):837–45.PubMedGoogle Scholar
  65. 65.
    Markel G, Ortenberg R, Seidman R, et al. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother. 2010;59(2):215–30.PubMedGoogle Scholar
  66. 66.
    Markel G, Lieberman N, Katz G, et al. CD66a interactions between human melanoma and NK Cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 2002;168(6):2803–10.PubMedGoogle Scholar
  67. 67.
    Markel G, Seidman R, Stern N, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol. 2006;177(9):6062–71.PubMedGoogle Scholar
  68. 68.
    Möller MJ, Kammerer R, Grunert F, et al. Biliary glycoprotein (BGP) expression on T cells and on a natural-killer-cell sub-population. Int J Cancer. 1996;65(6):740–5.PubMedGoogle Scholar
  69. 69.
    Ortenberg R, Sapir Y, Raz L, et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Therap. 2012;11(6):1300–10.Google Scholar
  70. 70.
    Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876–83.PubMedGoogle Scholar
  71. 71.
    Jensen SM, Maston LD, Gough MJ, et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol. 2010;37(5):524–32.PubMedGoogle Scholar
  72. 72.
    Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther. 2012;11(5):1062–70.PubMedGoogle Scholar
  73. 73.
    Chen AI, McAdam AJ, Buhlmann JE, et al. Ox40-ligand has a critical costimulatory role in dendritic cell: t cell interactions. Immunity. 1999;11(6):689–98.PubMedGoogle Scholar
  74. 74.
    Stüber E, Neurath M, Calderhead D, et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity. 1995;2(5):507–21.PubMedGoogle Scholar
  75. 75.
    Weinberg AD, Wegmann KW, Funatake C, et al. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 1999;162(3):1818–26.PubMedGoogle Scholar
  76. 76.
    Humphreys IR, Loewendorf A, de Trez C, et al. OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T cells: a CD4-dependent mechanism. J Immunol. 2007;179(4):2195–202.PubMedGoogle Scholar
  77. 77.
    Weinberg AD, Rivera M-M, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 2000;164(4):2160–9.PubMedGoogle Scholar
  78. 78.
    Laderach D, Wesa A, Galy A. 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol. 2003;226(1):37–44.PubMedGoogle Scholar
  79. 79.
    Langstein J, Michel J, Fritsche J, et al. CD137 (ILA/4-1BB), a member of the TNF receptor family regulates monocyte activation via reverse signaling. J Immunol. 1998;160:2488–94.PubMedGoogle Scholar
  80. 80.
    Sica G, Chen L. Modulation of the immune response through 4-1BB. Adv Exp Med Biol. 2000;465:355–62.PubMedGoogle Scholar
  81. 81.
    Kim J, Averbook B, Chambers K, et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res. 2001;61(5):2031–7.PubMedGoogle Scholar
  82. 82.
    Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol. 2008;26(15S (May 20 Supplement)):abstract 3007.Google Scholar
  83. 83.
    Ascierto PA, Simeone E, Sznol M, et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010;37(5):508–16.PubMedGoogle Scholar
  84. 84.
    Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676–80.PubMedGoogle Scholar
  85. 85.
    Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308.PubMedGoogle Scholar
  86. 86.
    Dudley ME, Wunderlich JR, Robbins PF, et al. cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.PubMedGoogle Scholar
  87. 87.
    Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–9.PubMedGoogle Scholar
  88. 88.
    Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16(9):2646–55.PubMedGoogle Scholar
  89. 89.
    Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346–57.PubMedGoogle Scholar
  90. 90.
    Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18(24):6758–70.PubMedGoogle Scholar
  91. 91.
    Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010;33(1):1–7.PubMedGoogle Scholar
  92. 92.
    Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancerm—what clinicians need to know. Nat Rev Clin Oncol. 2011;8(10):577–85.PubMedGoogle Scholar
  93. 93.
    Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332–42.PubMedGoogle Scholar
  94. 94.
    Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163(1):507–13.PubMedGoogle Scholar
  95. 95.
    Thomas S, Stauss HJ, Morris EC. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology. 2010;129(2):170–7.PubMedGoogle Scholar
  96. 96.
    Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011;29(11):550–7.PubMedGoogle Scholar
  97. 97.
    Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Nat Acad Sci. 1989;86(24):10024–8.PubMedGoogle Scholar
  98. 98.
    Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535–46.PubMedGoogle Scholar
  99. 99.
    Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264–70.PubMedGoogle Scholar
  100. 100.
    Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102.PubMedGoogle Scholar
  101. 101.
    Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261–71.PubMedGoogle Scholar
  102. 102.
    Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–6.PubMedGoogle Scholar
  103. 103.
    Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24.PubMedGoogle Scholar
  104. 104.
    Caballero OL, Chen Y-T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014–21.PubMedGoogle Scholar
  105. 105.
    Burns WR, Zhao Y, Frankel TL, et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 2010;70(8):3027–33.PubMedGoogle Scholar
  106. 106.
    Zhang L, Kerkar SP, Yu Z, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011;19(4):751–9.PubMedGoogle Scholar
  107. 107.
    Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386–94.PubMedGoogle Scholar
  108. 108.
    Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-Cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70(13):5213–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Dragoslav Zikich
    • 1
  • Jacob Schachter
    • 1
  • Michal J. Besser
    • 1
    • 2
  1. 1.Ella Institute for Melanoma, Sheba Medical CenterRamat-GanIsrael
  2. 2.Department of Clinical Microbiology and Immunology, Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations